Your browser doesn't support javascript.
loading
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
Bajaj, Jasmohan S; Sikaroodi, Masoumeh; Shamsaddini, Amirhossein; Henseler, Zachariah; Santiago-Rodriguez, Tasha; Acharya, Chathur; Fagan, Andrew; Hylemon, Phillip B; Fuchs, Michael; Gavis, Edith; Ward, Tonya; Knights, Dan; Gillevet, Patrick M.
Afiliación
  • Bajaj JS; Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA jasmohan@gmail.com.
  • Sikaroodi M; Microbiome Analysis Center, George Mason University, Manassas, Virginia, USA.
  • Shamsaddini A; Microbiome Analysis Center, George Mason University, Manassas, Virginia, USA.
  • Henseler Z; Diversigen, New Brighton, Minnesota, USA.
  • Santiago-Rodriguez T; Diversigen, New Brighton, Minnesota, USA.
  • Acharya C; Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.
  • Fagan A; Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.
  • Hylemon PB; Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.
  • Fuchs M; Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.
  • Gavis E; Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.
  • Ward T; Diversigen, New Brighton, Minnesota, USA.
  • Knights D; Diversigen, New Brighton, Minnesota, USA.
  • Gillevet PM; Department of Computer Science and Engineering, U, University of Minnesota, Minneapolis, MN, USA.
Gut ; 70(6): 1162-1173, 2021 06.
Article en En | MEDLINE | ID: mdl-32998876
OBJECTIVE: Altered bacterial composition is associated with disease progression in cirrhosis but the role of virome, especially phages, is unclear. DESIGN: Cross-sectional and pre/post rifaximin cohorts were enrolled. Cross-sectional: controls and cirrhotic outpatients (compensated, on lactulose (Cirr-L), on rifaximin (Cirr-LR)) were included and followed for 90-day hospitalisations. Pre/post: compensated cirrhotics underwent stool collection pre/post 8 weeks of rifaximin. Stool metagenomics for bacteria and phages and their correlation networks were analysed in controls versus cirrhosis, within cirrhotics, hospitalised/not and pre/post rifaximin. RESULTS: Cross-sectional: 40 controls and 163 cirrhotics (63 compensated, 43 Cirr-L, 57 Cirr-LR) were enrolled. Cirr-L/LR groups were similar on model for end-stage liver disease (MELD) score but Cirr-L developed greater hospitalisations versus Cirr-LR (56% vs 30%, p=0.008). Bacterial alpha/beta diversity worsened from controls through Cirr-LR. While phage alpha diversity was similar, beta diversity was different between groups. Autochthonous bacteria linked negatively, pathobionts linked positively with MELD but only modest phage-MELD correlations were seen. Phage-bacterial correlation network complexity was highest in controls, lowest in Cirr-L and increased in Cirr-LR. Microviridae and Faecalibacterium phages were linked with autochthonous bacteria in Cirr-LR, but not Cirr-L hospitalised patients had greater pathobionts, lower commensal bacteria and phages focused on Streptococcus, Lactococcus and Myoviridae. Pre/post: No changes in alpha/beta diversity of phages or bacteria were seen postrifaximin. Phage-bacterial linkages centred around urease-producing Streptococcus species collapsed postrifaximin. CONCLUSION: Unlike bacteria, faecal phages are sparsely linked with cirrhosis characteristics and 90-day outcomes. Phage and bacterial linkages centred on urease-producing, ammonia-generating Streptococcus species were affected by disease progression and rifaximin therapy and were altered in patients who experienced 90-day hospitalisations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encefalopatía Hepática / Enfermedad Hepática en Estado Terminal / Firmicutes / Rifaximina / Cirrosis Hepática / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gut Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encefalopatía Hepática / Enfermedad Hepática en Estado Terminal / Firmicutes / Rifaximina / Cirrosis Hepática / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Gut Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...